PF643 CHARACTERIZATION OF FRONTLINE TREATMENT PATTERNS AND THE PROPORTION OF PATIENTS REACHING SUBSEQUENT LINES OF THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Voorhees, P.M., Fonseca, R., Cote, S., Lam, A., Ukropec, J., Maiese, E., Potluri, R., Nair, S., Mehra, M.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics
S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia
Published in Hematology reports (01.09.2020)
Get full text
Published in Hematology reports (01.09.2020)
Journal Article
PS1372 B‐CELL MATURATION ANTIGEN ANTIBODY‐DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY
Popat, R., Lendvai, N., Trudel, S., Voorhees, P.M., Reeves, B., Libby, E.N., Richardson, P.G., Jr, L.D. Anderson, Sutherland, H.J., Yong, K., Hoos, A., Gorczyca, M.M., He, Z., Jewell, R.C., Dettman, E.J., Rigat, F., Gupta, I., Bragulat, V., Opalinska, J.B., Cohen, A.D.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article